Mediwound (MDWD)
NASDAQ:MDWD
Earnings Data
Report Date
May 27, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.65Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call reflects meaningful operational and strategic progress — a sixfold manufacturing capacity expansion, active Phase III enrollment for EscharEx, expanded indication work (DFU and pressure ulcers), numerous industry collaborations, substantive real-world data for NexoBrid, and a strengthened cash position following a $30M financing — all of which support a multiyear growth thesis. Offsetting these positives are near-term financial challenges: steep Q4 revenue decline (≈-67%), a full-year revenue drop (≈-16%), higher R&D spend and widening operating and EBITDA losses, reliance on government awards and pending regulatory approvals for the new facility, and elevated cash burn. Overall, operational momentum is evident but financial performance and timing risks temper the outlook.Company Guidance
Phase III VALUE Trial Progress
Enrollment ongoing in global Phase III VALUE study targeting 216 patients across ~40 U.S. and European sites; prespecified interim assessment and enrollment completion expected by year-end 2026, preserving ~90% statistical power.
Manufacturing Expansion for NexoBrid
Expanded manufacturing facility is operational and increases production capacity sixfold; commercial release from the site is subject to regulatory approvals expected in 2026, positioning the company to meet growing global demand and support stockpiling/national preparedness.
Strategic Collaborations and Industry Engagement
Multiple research collaborations with market-leading wound care companies (Coloplast/Kerecis, ConvaTec, Essity, Mölnlycke, Solventum, MiMedx and new collaboration with B. Braun for DFU Phase II) strengthen development, broaden clinical footprint, and support market access.
Clinical and Real-World Evidence Supporting NexoBrid
NexoBrid utilization across 70+ U.S. burn centers (majority of Vericel's ~90 target accounts); Israel Defense Forces data (~5,000 combat casualties) show clinical applicability in 71% of war-related injuries; prospective data show >90% reduction in embedded particles in ablation/blast injuries; 15-year military analysis reported a 50% increase in proportion of severe burns among wounded soldiers.
Strengthened Cash Position and Financing
Cash, cash equivalents and deposits of $53.6M at 12/31/2025 versus $43.6M at 12/31/2024 (≈+23%); completed $30.0M registered direct offering plus $3.5M from Series A warrant exercises, supporting runway amid continued investment.
Reaffirmed Multiyear Revenue Guidance
Company reaffirmed guidance: $24M–$26M for 2026, $32M–$35M for 2027, and $50M–$55M for 2028; guidance assumes continued support from BARDA and U.S. Department of War and potential initial EscharEx contribution in 2028.
Improved Full-Year Gross Margin
Full-year 2025 gross profit of $3.3M (19.2% margin) versus $2.6M (13.0% margin) in 2024 — gross profit increased ≈27% year-over-year with a margin improvement of +6.2 percentage points.
MDWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $17.60 | $17.45 | -0.85% |
Nov 20, 2025 | $17.86 | $16.86 | -5.60% |
Aug 14, 2025 | $18.75 | $18.57 | -0.96% |
May 21, 2025 | $20.87 | $19.89 | -4.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mediwound (MDWD) report earnings?
Mediwound (MDWD) is schdueled to report earning on May 27, 2026, Before Open (Confirmed).
What is Mediwound (MDWD) earnings time?
Mediwound (MDWD) earnings time is at May 27, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDWD EPS forecast?
MDWD EPS forecast for the fiscal quarter 2026 (Q1) is -0.65.